Teva Secures U.S. Rights to Two Samsung Bioepis Immunology Biosimilars Under 2026 Licensing Deal
Teva gains U.S. rights to Samsung Bioepis biosimilars infliximab-abda and etanercept-ykro under a 2026 licensing deal covering autoimmune and inflammatory
Research Desk
Teva Pharmaceutical Industries Ltd. and Samsung Bioepis Co., Ltd. have entered into a license and commercialization agreement for two FDA-approved immunology biosimilars, the companies announced on November 3, 2026, in a joint statement issued from Tel Aviv, Israel, and Incheon, South Korea.
Teva to Gain U.S. Rights to Samsung Bioepis Biosimilars
The products covered are infliximab-abda, a biosimilar to Remicade (infliximab), and ETICOVO (etanercept-ykro), a biosimilar to Enbrel (etanercept). The arrangement follows a staged structure.
Teva will receive U.S. commercialization rights to etanercept-ykro at closing, while rights to infliximab-abda will move to Teva in the third quarter of 2027. When Teva will begin commercializing etanercept-ykro in the United States has not yet been determined and will be announced at a later date.
Throughout, Samsung Bioepis remains responsible for regulatory oversight and manufacturing of both medicines. The transaction is subject to customary closing conditions, including the receipt of necessary regulatory approvals, and is anticipated to close by the end of 2026.
What Each Biosimilar Is Approved to Treat
Both products belong to a class of medicines known as tumor necrosis factor (TNF) inhibitors, indicated for chronic inflammatory and autoimmune conditions.
Infliximab-abda received FDA approval in 2017. Its approved indications include Crohn's disease in adult and pediatric patients, ulcerative colitis in adult and pediatric patients, rheumatoid arthritis in combination with methotrexate, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.
Teva will newly take on commercialization of the product, with the transfer taking effect in the third quarter of 2027.
Etanercept-ykro was FDA-approved in 2019 but is not currently marketed in the United States. It is approved for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis in patients aged two years and older, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis in patients aged four years and older.
Safety Information Associated With Infliximab-abda
The safety labeling for infliximab-abda carries warnings relevant to patients and prescribers.
According to the provided safety information, patients treated with infliximab products face an increased risk of serious infections that may lead to hospitalization or death. Most patients who developed such infections were also taking concomitant immunosuppressants such as methotrexate or corticosteroids.
Infections reported in connection with infliximab products include active tuberculosis, including reactivation of latent tuberculosis, and invasive fungal infections, among them histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, pneumocystosis, and cryptococcosis.
Patients should be tested for latent tuberculosis before use and during therapy, and treatment for latent infection should be initiated before starting the medicine. Infliximab-abda is to be discontinued if a patient develops a serious infection or sepsis.
How the Companies Will Share Value
The financial architecture of the deal involves staged and conditional payments. Under the agreement and subject to certain conditions, Teva will pay Samsung Bioepis an upfront payment spread over the next three years. Samsung Bioepis may also receive additional payments tied to launch and sales milestones. Profits from the commercialization of the two products will be shared between the companies.
Executives Frame the Strategic Logic
Leadership at both companies positioned the agreement as a deepening of an existing alliance rather than a one-off transaction.
Richard Francis, President and CEO of Teva, said the agreement strengthens the company's collaboration with Samsung Bioepis and will expand its U.S. immunology portfolio with two additional biologic treatment options.
Francis described biosimilars as an important component of Teva's Pivot to Growth strategy, serving to build a stronger portfolio while expanding access to high-quality medicines. He added that, together, the companies have an opportunity to bring more treatment choices to patients living with chronic inflammatory conditions.
Kyung-Ah Kim, President and CEO of Samsung Bioepis, said the company is delighted to expand its strategic alliance with Teva to strengthen the U.S. commercial footprint of its immunology portfolio.
Kim noted that infliximab-abda has built a proven track record of clinical efficacy and supply reliability since its launch, while ETICOVO is an FDA-approved therapy positioned to broaden treatment choices for patients.
By combining Samsung Bioepis' focus on high-quality biologic development and manufacturing with Teva's commercial reach across U.S. healthcare channels, Kim said the company aims to ensure uninterrupted treatment continuity for existing patients and deliver sustainable value to the U.S. healthcare system.
The Latest in a Growing Line of Deals
The newly announced agreement does not stand alone. It extends a series of biosimilar collaborations between the two companies in recent years.
In 2025, Teva and Samsung Bioepis announced a U.S. agreement covering EPYSQLI (eculizumab-aagh), a biosimilar to Soliris (eculizumab). In 2026, the partnership widened further with two additional agreements.
One covers OPUVIZ (aflibercept) in Canada. The other is a global agreement to license, develop, and commercialize up to six potential biosimilar candidates in early-stage development, including candidates referencing Fasenra (benralizumab) and Ilaris (canakinumab).
Teva characterized the latest transaction as an expansion of its collaboration with Samsung Bioepis, strengthening its generics powerhouse and biosimilars portfolio under the Pivot to Growth strategy. Teva shares trade on the New York Stock Exchange and the Tel Aviv Stock Exchange under the ticker TEVA.
Tracked in the database
Licensing and Commercialization Agreement · North America
Licensing and Commercialization Agreement
North America
Chemical
4 November 2026
4 min read
Tagged
Also read
Biocon Secures European Commission Approval for Pertuzumab Biosimilar Pebrilzo in HER2-Positive Breast Cancer
Nanoform Partners With European CDMO to Manufacture High-Concentration Biologics Under GMP in Germany
LOTTE Biologics Signs First Commercial Manufacturing Agreement for Songdo Plant 1 in South Korea
Live from the tracker
The projects behind these stories
Capacity, capex, stage, contractors and verified contacts for every project we track, updated daily.